By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Chugai Pharmaceutical Co., Ltd. (Japan) 

1-9, Kyobashi 2-chome

Chuo-ku  Tokyo  104-8301  Japan
Phone: 81-3-3281-6611 Fax: 81-3-3281-2828


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals





Company News
Chugai Pharma And Berlin-Chemie - The Menarini Group Announce Global License Agreement For An Anti-Cancer Agent, PA799 11/28/2016 12:55:22 PM
Chugai Pharma's ACTEMRA/RoACTEMRA Receives Breakthrough Therapy Designation From U.S. FDA For Giant Cell Arteritis 10/5/2016 10:35:21 AM
Chugai Pharma's Alecensa Receives Breakthrough Therapy Designation From FDA For First-Line Treatment Of ALK Positive Non-Small Cell Lung Cancer 10/4/2016 12:23:22 PM
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A 7/28/2016 10:26:22 AM
Chugai Pharma And Galderma Pharma S.A. Announce Global License Agreement For Nemolizumab (CIM331), Novel Biologic For Skin Diseases 7/21/2016 9:48:44 AM
Chugai Pharma Announces License Agreement For Recycling Antibody SA237 6/1/2016 12:21:25 PM
Chugai Pharma's Bispecific Antibody "ACE910/Emicizumab" Phase I Data In Patients With Hemophilia A Published In The New England Journal of Medicine Online 5/26/2016 11:30:26 AM
Comprehensive Collaboration Agreement Between Osaka University And Chugai Pharma 5/19/2016 12:08:04 PM
Chugai Pharma To Present Japanese Phase III Results On Alecensa At ASCO 5/19/2016 12:03:06 PM
Chugai Pharma Announces Phase II Global Study Results Of Nemolizumab (CIM331) In Late-Breaking Research Forums At AAD 3/7/2016 11:30:40 AM
123456789
//-->